Nuwellis, Inc. (NASDAQ:NUWE – Free Report) – Research analysts at Roth Capital decreased their Q1 2025 earnings per share (EPS) estimates for Nuwellis in a report issued on Tuesday, March 11th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.45) per share for the quarter, down from their prior estimate of ($0.30). The consensus estimate for Nuwellis’ current full-year earnings is ($8.17) per share. Roth Capital also issued estimates for Nuwellis’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at $0.09 EPS, FY2028 earnings at $0.78 EPS and FY2029 earnings at $1.41 EPS.
Nuwellis Price Performance
Shares of NASDAQ NUWE opened at $1.15 on Thursday. The stock has a market capitalization of $5.03 million, a price-to-earnings ratio of -0.01 and a beta of 0.36. The firm’s 50 day simple moving average is $1.22 and its 200-day simple moving average is $1.34. Nuwellis has a 12 month low of $0.92 and a 12 month high of $16.63.
Institutional Trading of Nuwellis
About Nuwellis
Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
Further Reading
- Five stocks we like better than Nuwellis
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- What Makes a Stock a Good Dividend Stock?
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What is the Dow Jones Industrial Average (DJIA)?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.